| Literature DB >> 32159517 |
Yoon Kim1, Jinserk Seo2, So-Yeon An3, Dong Hyun Sinn4, Ji Hye Hwang1.
Abstract
BACKGROUND: Exercise is predicted to have a positive effect among hepatocellular carcinoma (HCC) patients. However, these patients are hesitant to start and build up an exercise program for one major reason: the vague fear of developing hepatic decompensation, a potentially fatal condition that can lead to death. Integrating mobile health (mHealth) with individualized exercise programs could be a possible option for promoting physical capacity among HCC patients.Entities:
Keywords: exercise; hepatocellular carcinoma; mHealth; physical activity; physical fitness; rehabilitation
Mesh:
Year: 2020 PMID: 32159517 PMCID: PMC7097723 DOI: 10.2196/14435
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.773
Figure 1App screenshots and configuration. Screenshots of the main page (far left) and exercise management page (middle right) are shown, along with respective diagrams of explanations to the right of each screenshot.
Figure 2Procedure for adjusting participants' individually prescribed rehabilitation exercise programs in the mHealth app. 6MWT: 6-minute walk test.
Demographic and clinical characteristics of participants, (N=31).
| Characteristic | Value | |
| Age (years), mean (SD) | 56.7 (7.7) | |
|
|
| |
|
| Male | 26 (84) |
|
| Female | 5 (16) |
| Height (cm), mean (SD) | 166.9 (8.2) | |
| Weight (kg), mean (SD) | 71.0 (11.3) | |
| Body mass index (kg/m2), mean (SD) | 25.39 (3.00) | |
| Body fat (%), mean (SD) | 26.29 (8.01) | |
| Muscle mass (kg), mean (SD) | 28.98 (5.20) | |
|
|
| |
|
| Liver cirrhosis | 24 (77) |
|
| Chronic viral hepatitis | 5 (16) |
|
| Nonalcoholic fatty liver disease | 1 (3) |
|
| Alcoholic liver disease | 1 (3) |
|
|
| |
|
| 0-6 months ago | 5 (16) |
|
| 6 months-1 year ago | 3 (10) |
|
| 1-3 years ago | 11 (35) |
|
| 3-5 years ago | 8 (26) |
|
| More than 5 years ago | 4 (13) |
|
|
| |
|
| Diabetes mellitus | 7 (23) |
|
| Hypertension | 10 (32) |
|
| Dyslipidemia | 1 (3) |
|
| Cardiopulmonary disease | 1 (3) |
|
|
| |
|
| None | 25 (81) |
|
| More than once | 6 (19) |
|
|
| |
|
| Locoregional therapies (ie, transarterial chemoembolization or radiofrequency ablation) | 3 (10) |
|
| Surgery | 17 (55) |
|
| Combination treatment | 11 (35) |
Changes in physical fitness measures.
| Measure | Baseline, mean (SD) | 6 weeks, mean (SD) | 12 weeks, mean (SD) | Baseline vs 6 weeks, | 6 weeks vs 12 weeks, | Baseline vs 12 weeks, |
| Grip strength (kg) | 39.35 (9.98) | 39.98 (9.69) | 41.10 (10.52) | .69 | .31 | .02 |
| 30-second chair stand test (seconds) | 18.10 (3.29) | 20.55 (3.03) | 23.26 (3.79) | <.001 | <.001 | <.001 |
| 6-minute walk test (meters) | 572.90 (49.15) | 591.19 (49.61) | 604.07 (51.59) | <.001 | .01 | <.001 |
Figure 3Changes in physical fitness measures. BL: baseline; wks: weeks.
Changes in body composition and self-reported physical activity.
| Measure | Baseline, mean (SD) | 12 weeks, mean (SD) | |
| Body mass index (kg/m2) | 25.39 (3.00) | 25.57 (3.08) | .08 |
| Body fat (%) | 26.29 (8.01) | 26.07 (7.86) | .51 |
| Muscle mass (kg) | 28.98 (5.15) | 29.34 (5.31) | .03 |
| IPAQ-SFa (METsb) | 2031.95 (2236.60) | 3479.71 (2640.08) | .01 |
aIPAQ-SF: International Physical Activity Questionnaire-Short Form.
bMETs: metabolic equivalents.
Figure 4Changes in body composition and self-reported physical activity. BL: baseline; BMI: body mass index; IPAQ-SF: International Physical Activity Questionnaire-Short Form; METs: metabolic equivalents.
Changes in quality of life.
| EORTC-QLQ-C30a item | Score at baseline, mean (SD) | Score at 12 weeks, mean (SD) | ||
| Global health status and quality of lifeb | 72.50 (17.52) | 74.44 (17.63) | .43 | |
|
|
| |||
|
| Physical functioning | 85.77 (10.31) | 87.55 (11.30) | .43 |
|
| Role functioning | 87.22 (13.62) | 89.44 (16.65) | .38 |
|
| Emotional functioning | 84.16 (18.48) | 87.50 (12.90) | .28 |
|
| Cognitive functioning | 80.55 (13.19) | 86.11 (11.64) | .06 |
|
| Social functioning | 85.55 (24.65) | 93.33 (12.06) | .08 |
|
|
|
|
| |
|
| Fatigue | 25.18 (12.69) | 23.33 (15.25) | .48 |
|
| Nausea and vomiting | 2.22 (5.76) | 2.17 (6.31) | .66 |
|
| Pain | 10.55 (14.17) | 6.11 (11.14) | .04 |
|
| Dyspnea | 22.22 (26.74) | 17.77 (24.34) | .35 |
|
| Insomnia | 15.55 (22.71) | 14.44 (20.86) | .80 |
|
| Appetite loss | 6.66 (16.14) | 5.55 (12.63) | .71 |
|
| Constipation | 12.00 (17.83) | 11.11 (15.98) | .80 |
|
| Diarrhea | 12.00 (17.83) | 11.11 (15.98) | .71 |
|
| Financial difficulties | 13.33 (25.67) | 7.77 (16.80) | .20 |
aEORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire C30.
bHigher scores imply positive results.
cLower scores imply positive results.